In 2017 the Oxford Antibiotic Group was founded as a bio-pharmaceutical development company by an international founding team to dedicate itself to the discovery and development of bioactive compounds.

With the novel approach called Logi-biotic®, the company uses nature and its active ingredient strategies, which have been optimized through evolution, as the ideal source for finding innovative drug candidates.

Based on this natural combinatorial library, the company has developed various programs in the field of antibiotics, antiviral substances and neurological diseases such as Alzheimer’s and Parkinson’s.